These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Stopping CMV prophylaxis with HAART.
    Journal: TreatmentUpdate; 1998 Sep; 10(7):4-6. PubMed ID: 11365782.
    Abstract:
    Preliminary data indicates that the use of highly active antiretroviral therapy (HAART) in people with AIDS may prolong remission of CMV retinitis by causing the CD4+ cells to rise above 100. This increase in CD4+ cells creates a natural protection against CMV in most cases, allowing patients to discontinue maintenance therapy for CMV retinitis. In eight subjects, HAART took between 4 and 12 months to raise CD4+ counts over 100. No participant had a recurrence of retinitis during the study, which lasted 1 year. This increase in CD4+ cells, and cessation of maintenance therapy, seemed effective only with patients who had retinal pigment epithelial(RPE) scarring, rather than retinal whitening or cloudy borders.
    [Abstract] [Full Text] [Related] [New Search]